Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of the American Heart Association|October 30, 2018
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE TrialWilliam B White, Fatima Jalil, William C Cushman, et al.
Toxicology Letters|May 27, 2005
Occupational exposure to polycyclic aromatic hydrocarbons in German industries: association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphismsHans-Peter Rihs, Beate Pesch, Martin Kappler, et al.
International Journal of Hygiene and Environmental Health|June 24, 2005
DNA adduct formation of benzo[a]pyrene in white blood cells of workers exposed to polycyclic aromatic hydrocarbonsThomas Mensing, Boleslaw Marczynski, Beate Engelhardt, et al.
Circulation|October 26, 2018
Reassessing the Role of Surrogate End Points in Drug Development for Heart FailureStephen J Greene, Robert J Mentz, Mona Fiuzat, et al.
Diabetes, Obesity & Metabolism|October 25, 2017
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trialYou-Cheol Hwang, David A Morrow, Christopher P Cannon, et al.
Archives of Toxicology|May 20, 2006
Irritative effects of fumes and aerosols of bitumen on the airways: results of a cross-shift studyMonika Raulf-Heimsoth, Beate Pesch, Klaus Schott, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
Assessment of DNA damage in WBCs of workers occupationally exposed to fumes and aerosols of bitumenBoleslaw Marczynski, Monika Raulf-Heimsoth, Ralf Preuss, et al.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 DiabetesMary Jane Geiger, Cyrus Mehta, J Rick Turner, et al.
Pageof 5